Ribo Life Science Repurchases 171,800 Shares for HK$9.35 Million

Ribo Life Science-B (06938.HK) conducted a share repurchase on September 11, 2026, purchasing 171,800 of its own shares for a total consideration of HK$9.348 million, according to a company filing.

Buyback Details

The transaction was executed on the open market of the Hong Kong Stock Exchange. The figures from the announcement break down as follows:

• Total Expenditure: HK$9.348 million
• Shares Repurchased: 171,800
• Average Price Paid: Approximately HK$54.41 per share

This buyback represents a deployment of the company's capital to acquire its own equity, thereby reducing the number of shares available for public trading.

Ad

Market Implications

Share repurchases are a common tool for companies to return value to shareholders. Such actions are often interpreted by the market as a sign that management believes the company's stock is undervalued.

By reducing the total number of outstanding shares, buybacks can also have an accretive effect on key financial metrics like earnings per share (EPS). As a pre-profit biotechnology firm listed under Chapter 18A of the HKEX rules (indicated by the "-B" marker), Ribo Life Science's use of capital for a repurchase, rather than solely for research and development, is a strategic decision that will be noted by investors.